for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

Oct 30 (Reuters) - ARGENX NV:

* ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113

* PHASE I CLINICAL TRIAL WILL ENROLL UP TO 32 HEALTHY VOLUNTEERS

* TOPLINE DATA FOR MYASTHENIA GRAVIS AND IMMUNE THROMBOCYTOPENIA EXPECTED IN Q1 AND SECOND HALF OF 2018

* INTERIM RESULTS FROM PEMPHIGUS VULGARIS TRIAL EXPECTED DURING SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up